Astrazeneca PLC (NYSE:AZN) – Analysts at Jefferies Group increased their FY2017 earnings estimates for shares of Astrazeneca PLC in a research report issued on Tuesday. Jefferies Group analyst J. Holford now expects that the company will earn $1.89 per share for the year, up from their previous estimate of $1.85. Jefferies Group has a “Hold” rating on the stock. Jefferies Group also issued estimates for Astrazeneca PLC’s FY2021 earnings at $2.72 EPS.
Other research analysts have also issued research reports about the stock. UBS AG lowered shares of Astrazeneca PLC from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $35.44 to $25.55 in a research report on Wednesday, April 5th. BidaskClub lowered shares of Astrazeneca PLC from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. Morgan Stanley lowered shares of Astrazeneca PLC from an “overweight” rating to an “equal weight” rating in a research report on Friday, July 28th. Barclays PLC restated an “overweight” rating on shares of Astrazeneca PLC in a research report on Thursday, July 13th. Finally, Pareto Securities upgraded shares of Astrazeneca PLC from a “sell” rating to a “hold” rating in a research report on Tuesday. Four research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $33.39.
ILLEGAL ACTIVITY NOTICE: This news story was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://theolympiareport.com/2017/08/13/equities-analysts-issue-forecasts-for-astrazeneca-plcs-fy2017-earnings-nyseazn-updated.html.
Shares of Astrazeneca PLC (NYSE AZN) traded up 0.115% on Thursday, reaching $30.365. 1,245,032 shares of the company’s stock were exchanged. Astrazeneca PLC has a 12 month low of $25.55 and a 12 month high of $35.60. The company has a market cap of $76.88 billion, a price-to-earnings ratio of 19.918 and a beta of 0.74. The firm’s 50-day moving average price is $33.57 and its 200 day moving average price is $31.37.
Astrazeneca PLC (NYSE:AZN) last released its earnings results on Thursday, July 27th. The company reported $0.87 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.46. The business had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. The firm’s revenue was down 9.9% on a year-over-year basis. During the same quarter last year, the company earned $0.83 earnings per share.
The firm also recently disclosed a None dividend, which will be paid on Monday, September 11th. Shareholders of record on Friday, August 11th will be paid a $0.44 dividend. This represents a dividend yield of 2.98%. The ex-dividend date of this dividend is Wednesday, August 9th. Astrazeneca PLC’s dividend payout ratio (DPR) is 44.92%.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Pinnacle Financial Partners Inc. raised its position in Astrazeneca PLC by 2.5% in the second quarter. Pinnacle Financial Partners Inc. now owns 9,233 shares of the company’s stock worth $314,000 after buying an additional 229 shares during the last quarter. Garrison Financial Corp raised its position in Astrazeneca PLC by 0.5% in the second quarter. Garrison Financial Corp now owns 18,058 shares of the company’s stock worth $616,000 after buying an additional 86 shares during the last quarter. Berkeley Capital Partners LLC raised its position in Astrazeneca PLC by 3.7% in the second quarter. Berkeley Capital Partners LLC now owns 34,644 shares of the company’s stock worth $1,181,000 after buying an additional 1,233 shares during the last quarter. Carnick & Kubik Group LLC raised its position in Astrazeneca PLC by 8.4% in the second quarter. Carnick & Kubik Group LLC now owns 37,757 shares of the company’s stock worth $1,287,000 after buying an additional 2,935 shares during the last quarter. Finally, Wetherby Asset Management Inc. raised its position in Astrazeneca PLC by 11.0% in the second quarter. Wetherby Asset Management Inc. now owns 35,174 shares of the company’s stock worth $1,199,000 after buying an additional 3,478 shares during the last quarter. 14.39% of the stock is currently owned by hedge funds and other institutional investors.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Astrazeneca PLC and related companies with Analyst Ratings Network’s FREE daily email newsletter.